Lumos Pharma Analyst Ratings
Lumos Pharma Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/06/2023 | 797.44% | HC Wainwright & Co. | → $28 | Reiterates | Buy → Buy |
| 08/22/2023 | 220.51% | Cantor Fitzgerald | → $10 | Reiterates | Overweight → Overweight |
| 08/15/2023 | 220.51% | Cantor Fitzgerald | $14 → $10 | Maintains | Overweight |
| 08/10/2023 | 444.87% | Oppenheimer | $18 → $17 | Maintains | Outperform |
| 08/10/2023 | 797.44% | HC Wainwright & Co. | → $28 | Reiterates | Buy → Buy |
| 07/24/2023 | 348.72% | Cantor Fitzgerald | → $14 | Reiterates | Overweight → Overweight |
| 06/22/2023 | 797.44% | HC Wainwright & Co. | → $28 | Reiterates | Buy → Buy |
| 05/04/2023 | 797.44% | HC Wainwright & Co. | → $28 | Reiterates | → Buy |
| 03/06/2023 | 797.44% | HC Wainwright & Co. | → $28 | Reiterates | → Buy |
| 12/08/2022 | 124.36% | Jefferies | $17 → $7 | Downgrades | Buy → Hold |
| 11/15/2022 | 124.36% | Jefferies | → $7 | Downgrades | Buy → Hold |
| 07/20/2022 | 541.03% | Oppenheimer | → $20 | Initiates Coverage On | → Outperform |
| 11/04/2021 | 797.44% | HC Wainwright & Co. | $27 → $28 | Maintains | Buy |
| 07/21/2021 | 765.38% | HC Wainwright & Co. | $34 → $27 | Maintains | Buy |
| 03/11/2021 | 669.23% | Stifel | $4 → $24 | Upgrades | Hold → Buy |
| 12/03/2020 | 925.64% | Cantor Fitzgerald | → $32 | Initiates Coverage On | → Overweight |
| 11/23/2020 | 989.74% | HC Wainwright & Co. | $33 → $34 | Maintains | Buy |
| 08/26/2020 | 733.33% | Piper Sandler | → $26 | Initiates Coverage On | → Overweight |
| 08/04/2020 | 957.69% | HC Wainwright & Co. | → $33 | Initiates Coverage On | → Buy |
| 04/16/2020 | 284.62% | Jefferies | → $12 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 09/06/2023 | 797.44% | HC Wainwright公司 | →$28 | 重申 | 购买→购买 |
| 2023年08月22日 | 220.51% | 康托·菲茨杰拉德 | →$10 | 重申 | 超重→超重 |
| 2023年08月15日 | 220.51% | 康托·菲茨杰拉德 | $14→$10 | 维护 | 超重 |
| 2023年08月10日 | 444.87% | 奥本海默 | $18→$17 | 维护 | 跑赢大盘 |
| 2023年08月10日 | 797.44% | HC Wainwright公司 | →$28 | 重申 | 购买→购买 |
| 07/24/2023 | 348.72% | 康托·菲茨杰拉德 | →$14 | 重申 | 超重→超重 |
| 2023/06/22 | 797.44% | HC Wainwright公司 | →$28 | 重申 | 购买→购买 |
| 05/04/2023 | 797.44% | HC Wainwright公司 | →$28 | 重申 | →购买 |
| 03/06/2023 | 797.44% | HC Wainwright公司 | →$28 | 重申 | →购买 |
| 12/08/2022 | 124.36% | 杰富瑞 | $17→$7 | 评级下调 | 购买→Hold |
| 2022年11月15日 | 124.36% | 杰富瑞 | →$7 | 评级下调 | 购买→Hold |
| 07/20/2022 | 541.03% | 奥本海默 | →$20 | 开始承保 | →跑赢大盘 |
| 11/04/2021 | 797.44% | HC Wainwright公司 | $27→$28 | 维护 | 买 |
| 07/21/2021 | 765.38% | HC Wainwright公司 | $34→$27 | 维护 | 买 |
| 03/11/2021 | 669.23% | Stifel | $4→$24 | 升级 | 持有→购买 |
| 12/03/2020 | 925.64% | 康托·菲茨杰拉德 | →$32 | 开始承保 | →超重 |
| 11/23/2020 | 989.74% | HC Wainwright公司 | $33→$34 | 维护 | 买 |
| 2020/08/26 | 733.33% | 派珀·桑德勒 | →$26 | 开始承保 | →超重 |
| 08/04/2020 | 957.69% | HC Wainwright公司 | →$33 | 开始承保 | →购买 |
| 04/16/2020 | 284.62% | 杰富瑞 | →$12 | 开始承保 | →购买 |
What is the target price for Lumos Pharma (LUMO)?
Lumos Pharma(LUMO)的目标价是多少？
The latest price target for Lumos Pharma (NASDAQ: LUMO) was reported by HC Wainwright & Co. on September 6, 2023. The analyst firm set a price target for $28.00 expecting LUMO to rise to within 12 months (a possible 797.44% upside). 11 analyst firms have reported ratings in the last year.
鲁莫斯制药公司(纳斯达克代码：LUMO)的最新目标价是由HC Wainwright&Co.于2023年9月6日报道的。这家分析公司将目标价定为28美元，预计LUMO将在12个月内上涨(可能上涨797.44%)。过去一年，有11家分析公司公布了评级。
What is the most recent analyst rating for Lumos Pharma (LUMO)?
卢莫斯制药公司(Lumos Pharma)的最新分析师评级是多少？
The latest analyst rating for Lumos Pharma (NASDAQ: LUMO) was provided by HC Wainwright & Co., and Lumos Pharma reiterated their buy rating.
分析师对Lumos Pharma(纳斯达克代码：LUMO)的最新评级由HC Wainwright&Co.提供，Lumos Pharma重申其买入评级。
When is the next analyst rating going to be posted or updated for Lumos Pharma (LUMO)?
Lumos Pharma(LUMO)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Lumos Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Lumos Pharma was filed on September 6, 2023 so you should expect the next rating to be made available sometime around September 6, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公开财务报表，与Lumos Pharma的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Lumos Pharma的上一次评级是在2023年9月6日提交的，所以你应该预计下一次评级将在2024年9月6日左右的某个时候公布。
Is the Analyst Rating Lumos Pharma (LUMO) correct?
分析师对Lumos Pharma的评级正确吗？
While ratings are subjective and will change, the latest Lumos Pharma (LUMO) rating was a reiterated with a price target of $0.00 to $28.00. The current price Lumos Pharma (LUMO) is trading at is $3.12, which is within the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的Lumos Pharma(LUMO)评级被重申，目标价在0.00美元至28.00美元之间。Lumos Pharma目前的交易价格为3.12美元，在分析师的预测范围内。